Table 3.
Baseline | ANOVA vs AMD-P | 6 months | ANOVA vs baseline | |||||
---|---|---|---|---|---|---|---|---|
Mean | SD | f (1,27) | p | Mean | SD | f (1,27) | p | |
Central macular thickness (CRT, micron) | ||||||||
AMD-P (n = 14) | 273.85 | 24.68 | 275.00 | 26.10 | 0.01 | 0.909 | ||
AMD-M (n = 14) | 281.86 | 20.88 | 0.83 | 0.370 | 281.36 | 22.20 | 0.00 | 0.952 |
Central macular volume (CMV, mm3) | ||||||||
AMD-P (n = 14) | 0.21 | 0.014 | 0.21 | 0.016 | 0.06 | 0.805 | ||
AMD-M (n = 14) | 0.22 | 0.016 | 2.01 | 0.169 | 0.22 | 0.019 | 0.00 | 1.000 |
Central inner retinal thickness (C-IRT, micron) | ||||||||
AMD-P (n = 14) | 41.00 | 7.95 | 39.46 | 7.64 | 0.25 | 0.620 | ||
AMD-M (n = 14) | 42.00 | 5.71 | 0.14 | 0.709 | 40.57 | 6.73 | 0.37 | 0.550 |
Central inner retinal volume (C-IRV, mm3) | ||||||||
AMD-P (n = 14) | 0.031 | 0.01 | 0.032 | 0.01 | 0.07 | 0.793 | ||
AMD-M (n = 14) | 0.036 | 0.01 | 1.75 | 0.197 | 0.031 | 0.01 | 1.75 | 0.197 |
Central outer retinal thickness (C-ORT, micron) | ||||||||
AMD-P (n = 14) | 116.85 | 16.37 | 119.46 | 13.89 | 0.19 | 0.664 | ||
AMD-M (n = 14) | 122.14 | 15.02 | 0.77 | 0.389 | 123.71 | 12.33 | 0.09 | 0.765 |
Central outer retinal volume (C-ORV, mm3) | ||||||||
AMD-P (n = 14) | 0.089 | 0.01 | 0.091 | 0.01 | 0.28 | 0.601 | ||
AMD-M (n = 14) | 0.096 | 0.01 | 3.43 | 0.075 | 0.097 | 0.01 | 0.07 | 0.793 |
Subfoveal choroidal thickness (SCT, micron) | ||||||||
AMD-P (n = 14) | 228.31 | 50.34 | 228.46 | 58.77 | 0.00 | 0.994 | ||
AMD-M (n = 14) | 227.86 | 44.26 | 0.00 | 0.980 | 230.64 | 48.12 | 0.03 | 0.875 |
Temporal choroidal thickness (TCT, micron) | ||||||||
AMD-P (n = 14) | 239.31 | 64.66 | 232.15 | 56.69 | 0.09 | 0.767 | ||
AMD-M (n = 14) | 237.00 | 35.24 | 0.01 | 0.908 | 237.50 | 32.48 | 0.00 | 0.969 |
Nasal choroidal thickness (NCT, micron) | ||||||||
AMD-P (n = 14) | 217.77 | 59.69 | 210.00 | 69.94 | 0.09 | 0.763 | ||
AMD-M (n = 14) | 238.64 | 48.84 | 1.00 | 0.328 | 231.57 | 48.20 | 0.15 | 0.703 |
Mean ± standard deviation (SD) of spectral domain-optical coherence tomography (SD-OCT) values detected at baseline condition and after 6 months of follow-up in AMD eyes treated with placebo (AMD-P eyes) or with Macuprev® (AMD-M eyes). Statistics: one-way analysis of variance (ANOVA) between AMD-P and AMD-M groups at baseline and in AMD-P and AMD-M groups at 6 months vs baseline; n number of eyes